DIFLUPREDNATE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DIFLUPREDNATE (DIFLUPREDNATE).
Difluprednate is a potent corticosteroid that binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress inflammatory mediators.
| Metabolism | Primarily hepatic via CYP450 enzymes, with major metabolite being 6α-fluoroprednisolone acetate. |
| Excretion | Primarily renal (65–75% as metabolites), with biliary/fecal excretion accounting for 15–25%. |
| Half-life | Terminal elimination half-life approximately 2–4 hours; clinically, duration of action may extend due to receptor binding. |
| Protein binding | Approximately 90% bound to albumin and corticosteroid-binding globulin. |
| Volume of Distribution | Approximately 0.5–0.8 L/kg, indicating moderate tissue distribution. |
| Bioavailability | Topical: minimal systemic absorption (<5%); ophthalmic: <1% systemic bioavailability. |
| Onset of Action | Topical: within 2–3 hours for anti-inflammatory effect; ophthalmic: within 1–2 hours. |
| Duration of Action | Topical: 6–12 hours; ophthalmic: 4–8 hours depending on formulation and condition. |
| Molecular Weight | 508.6 |
Topical: Apply thin film to affected area twice daily.
| Dosage form | EMULSION |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No dose adjustment required for hepatic impairment. |
| Pediatric use | Apply thin film to affected area once or twice daily; limit use to smallest amount for shortest duration. |
| Geriatric use | Use with caution due to increased risk of skin atrophy; apply smallest amount for shortest duration. |
| 1st trimester | Use only if potential benefit justifies risk. Studies in animals have shown teratogenic effects; no adequate human studies. Corticosteroids are generally avoided in first trimester due to possible increased risk of cleft palate. |
| 2nd trimester | Use only if clearly needed. May cause fetal growth restriction, adrenal suppression, or other corticosteroid-related effects. Monitor fetal growth. |
| 3rd trimester | Use only if clearly needed. Prolonged use may lead to adrenal suppression in neonate. Late use associated with preterm labor? Not well studied. |
Clinical note
Comprehensive clinical and safety monograph for DIFLUPREDNATE (DIFLUPREDNATE).
| Placental transfer | Corticosteroids cross the placenta; degree varies by agent. Difluprednate is a potent corticosteroid; placental transfer is expected but not quantified in humans. Based on molecular weight (508.6 Da) and lipophilicity, crossing is probable. |
| Breastfeeding |
■ FDA Black Box Warning
No FDA boxed warning.
| Serious Effects |
Hypersensitivity to difluprednate or any component of the formulationActive viral (e.g., herpes simplex keratitis) or fungal infections of the eyeUntreated bacterial ocular infection
| Precautions | Increased intraocular pressure (IOP) with prolonged use, Risk of posterior subcapsular cataract formation, Delayed wound healing, Increased susceptibility to ocular infections (including fungal) and exacerbation of existing infections, Potential for corneal thinning and perforation, Adrenal suppression with systemic absorption |
| Food/Dietary | No known food interactions. |
| Clinical Pearls |
Loading safety data…
| Difluprednate is a corticosteroid; systemic absorption after topical ophthalmic use is minimal. However, if applied to large areas or broken skin, significant absorption may occur. Caution is advised. Monitor infant for signs of adrenal suppression if maternal dose is high. |
| Lactation Rating | L3 (Moderately Safe) - limited data, but low systemic absorption typical for ophthalmic use. |
| Teratogenic Risk | Difluprednate is a corticosteroid; systemic exposure is low with ophthalmic use. No adequate human studies. Animal studies show teratogenicity at high doses. FDA Pregnancy Category C. Theoretical risk of cleft palate if used in first trimester; avoid systemic absorption. Use only if potential benefit justifies risk. |
| Fetal Monitoring | Monitor intraocular pressure (IOP) regularly; corticosteroids may increase IOP. Monitor for cataract formation, secondary infection, and delayed wound healing. No specific fetal monitoring required due to low systemic absorption. |
| Fertility Effects | No human data on fertility effects. Animal studies have not been conducted specifically for difluprednate. Corticosteroids may affect hormonal balance; consider potential for menstrual irregularities or reduced fertility. |
| Difluprednate is a potent corticosteroid used primarily for postoperative ocular inflammation and pain. It is more lipophilic than prednisolone acetate, enhancing corneal penetration. Use with caution in patients with corneal epithelial defects or infections; monitor intraocular pressure closely as it can cause significant IOP elevation. Do not use in fungal or viral keratitis. Tapering is not required for short-term use but may be needed for prolonged therapy. |
| Patient Advice | Shake the bottle well before each use. · Do not touch the dropper tip to any surface to avoid contamination. · Remove contact lenses before instilling; wait 15 minutes before reinserting. · Use exactly as prescribed; do not stop abruptly without consulting your doctor. · Report any eye pain, vision changes, or redness that worsens. · Avoid driving immediately after use as vision may be blurred. |